Adage Capital Partners
VERA icon

Adage Capital Partners’s Vera Therapeutics VERA Stock Holding History

Adage Capital Partners’s Portfolio VERA Stock Details VERA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-480,000
Closed -$20.3M – 951
2024
Q4 		$20.3M Sell
480,000
-894,000
-65% -$39.6M 0.04% 443
2024
Q3 		$60.7M Buy
1,374,000
+255,000
+23% +$9.68M 0.11% 204
2024
Q2 		$40.5M Buy
1,119,000
+281,805
+34% +$11.2M 0.08% 260
2024
Q1 		$36.1M Buy
+837,195
New +$29.8M 0.07% 307

Other funds holding VERA

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

Adage Capital Partners's VERA Position: Q1 2025 in Review

Adage Capital Partners sold out of Vera Therapeutics (VERA) in Q1 2025, closing a stake of 480,000 shares — an estimated $20.3M sold.

Adage Capital Partners first reported a position in VERA in Q1 2024 and held it in 4 quarters. The position peaked at $60.7M in Q3 2024. 179 funds tracked by Wall St. Rank hold VERA as of Q1 2025.

  • Adage Capital Partners reported no remaining Vera Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Adage Capital Partners sold 480,000 Vera Therapeutics shares in Q1 2025, an estimated $20.3M.
  • Adage Capital Partners first reported a position in Vera Therapeutics in Q1 2024 and held it in 4 quarters.
  • Adage Capital Partners's Vera Therapeutics position peaked at $60.7M in Q3 2024.
  • 179 funds tracked by Wall St. Rank held Vera Therapeutics as of Q1 2025.

Based on Adage Capital Partners's 13F filing for Q1 2025, filed 15 May 2025.